2000 Participants Needed

Surgical Ablation for Atrial Fibrillation

(SAFE Trial)

RW
SC
Overseen BySAFE Coordinators
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Population Health Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the effectiveness of a procedure called surgical atrial fibrillation ablation for patients already undergoing heart surgery. It focuses on those with atrial fibrillation (an irregular and often rapid heart rate) who are having other heart surgeries, such as bypass or valve replacements. Some participants will receive the ablation during their surgery, while others will not, enabling researchers to assess its effectiveness. Suitable candidates have a history of atrial fibrillation and are already scheduled for specific types of heart surgery. As an unphased trial, this study provides patients the opportunity to contribute to important research that could enhance surgical outcomes for future heart surgery patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that surgical atrial fibrillation ablation is safe?

Research shows that surgical procedures for treating atrial fibrillation, such as the Cox-Maze procedure, are generally safe for patients. Studies have found that this procedure significantly improves the chances of maintaining a normal heart rhythm in people with atrial fibrillation (AF). Specifically, five years after the procedure, patients maintain normal heart rhythms 80% of the time, and 65% of the time after ten years.

The Cox-Maze procedure is considered a top choice for treating AF, indicating long-term safety. While success rates can vary, they are usually high, often exceeding 70%. This suggests the procedure is effective and well-tolerated by many patients.

Overall, these findings indicate that surgical atrial fibrillation ablation is generally safe, based on evidence from various studies.12345

Why are researchers excited about this trial?

Researchers are excited about the surgical ablation for atrial fibrillation because it offers a targeted approach during cardiac surgery. Unlike standard treatments like medication or non-surgical catheter ablation, this method involves directly ablating the left atrium while the patient is already undergoing surgery for another heart condition. This integrated approach could improve the precision and effectiveness of the treatment, potentially reducing the recurrence of atrial fibrillation. By incorporating the ablation into existing surgical procedures, it might also streamline patient care and recovery time.

What evidence suggests that surgical atrial fibrillation ablation is effective for atrial fibrillation?

This trial will compare outcomes for patients undergoing cardiac surgery with and without the addition of surgical atrial fibrillation ablation. Studies have shown that atrial fibrillation ablation effectively maintains a normal heartbeat. Specifically, the Cox-Maze IV procedure has been very successful, with over 70% of patients maintaining a normal heartbeat long-term. Research indicates that this procedure helps 80% of patients avoid irregular heartbeats for five years and 65% for ten years. Adding this procedure during heart surgery significantly increases the chances of maintaining a regular heartbeat compared to not having it. These findings suggest that surgical ablation is a promising option for patients with atrial fibrillation undergoing heart surgery.12346

Who Is on the Research Team?

RW

Richard Whitlock

Principal Investigator

Population Health Research Institute

EB

Emilie Belley-Côté

Principal Investigator

Population Health Research Institute

Are You a Good Fit for This Trial?

This trial is for adults over 18 with a history of paroxysmal or persistent atrial fibrillation who are already scheduled for certain heart surgeries like bypass grafting or aortic valve replacement. It's not open to those in long-term care, with very large left atria, primary atrial flutter, previous similar heart surgery, or needing complex procedures like transplants.

Inclusion Criteria

I am scheduled for heart surgery, such as bypass or valve replacement.
Provide informed consent
I have a history of irregular heartbeats.

Exclusion Criteria

My main heart rhythm problem is atrial flutter.
Your left atrial diameter is 6 centimeters or larger, as shown in medical records.
I have had heart surgery that involved opening the protective covering of the heart.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Surgery and Initial Hospitalization

Participants undergo cardiac surgery with or without surgical AF ablation and are monitored until hospital discharge

Up to hospital discharge
Inpatient stay

Post-operative Follow-up

Participants are followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals

4 years
Multiple visits at specified intervals

Long-term Follow-up

Participants are monitored for hospital readmissions with heart failure and other outcomes

4 years

What Are the Treatments Tested in This Trial?

Interventions

  • Surgical Atrial Fibrillation Ablation
Trial Overview The SAFE trial is testing the effectiveness of adding surgical ablation—a procedure that creates scars in the heart to prevent abnormal electrical signals—for treating atrial fibrillation during planned cardiac surgeries. This international study randomly assigns participants to receive this additional treatment.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Surgical Atrial Fibrillation Ablation GroupExperimental Treatment1 Intervention
Group II: No Surgical Atrial Fibrillation Ablation GroupActive Control1 Intervention

Surgical Atrial Fibrillation Ablation is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Surgical AF Ablation for:
🇺🇸
Approved in United States as Surgical AF Ablation for:
🇨🇦
Approved in Canada as Surgical AF Ablation for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Population Health Research Institute

Lead Sponsor

Trials
165
Recruited
717,000+

Hamilton Health Sciences Corporation

Collaborator

Trials
380
Recruited
345,000+

Published Research Related to This Trial

The Cox-maze procedure for treating atrial fibrillation (AF) in 61 patients showed a 4.9% in-hospital mortality rate and a 1.6% late mortality rate, indicating an acceptable surgical risk for this intervention.
Post-surgery, 70.5% of patients achieved stable sinus rhythm at the last evaluation, demonstrating the procedure's efficacy in restoring normal heart rhythm, although some patients experienced arrhythmias.
Results of the surgical treatment of chronic atrial fibrillation.Kalil, RA., Albrecht, A., Lima, GG., et al.[2019]
Current strategies for monitoring adverse events (AEs) in dermatologic surgery are inconsistent, with morbidity and mortality conferences being the most common reporting method, but more sensitive approaches like retrospective medical record reviews and anonymous electronic systems exist.
There is no standard for AE reporting in dermatologic surgery, highlighting the need for pilot studies to establish effective measures that can enhance AE detection and improve patient safety outcomes.
Detecting adverse events in dermatologic surgery.Pinney, D., Pearce, DJ., Feldman, SR.[2019]
The Cox-Maze IV procedure (CMP-IV) demonstrated excellent long-term efficacy in maintaining sinus rhythm in patients with atrial fibrillation (AF), with freedom from atrial tachyarrhythmia (ATA) rates of 92% at 1 year, 84% at 5 years, and 77% at 10 years based on a study of 853 patients.
Key predictors of ATA recurrence over 10 years included age, left atrial size, and the presence of nonparoxysmal AF, indicating that these factors should be considered when assessing patient outcomes after the CMP-IV procedure.
The long-term outcomes and durability of the Cox-Maze IV procedure for atrial fibrillation.Khiabani, AJ., MacGregor, RM., Bakir, NH., et al.[2023]

Citations

Maze Procedure Success Rates for Atrial FibrillationWhile they generally have high success rates of over 70%, reported success rates can vary for several reasons, including those below.
The long-term outcomes and durability of the Cox-Maze IV ...The CMP-IV had an excellent long-term efficacy at maintaining sinus rhythm. At late follow-up, the results of the CMP-IV remained superior to those reported for ...
Safety and efficacy of Cox‐Maze procedure for atrial fibrillation ...Our systematic review suggested that RCTs have demonstrated the addition of the Cox‐Maze procedure for AF leads to a significantly higher rate of sinus rhythm ...
The long-term outcomes of concomitant Cox-Maze IV ...The concomitant procedure provided good freedom from atrial tachyarrhythmias of 80% and 65% at years 5 and 10, respectively. The freedom from ...
Effectiveness of Maze IV procedure versus thoracoscopic ...This study aims to evaluate and compare the outcomes of TA and CMP-IV in treating AF.
Surgical options for atrial fibrillation treatment during ...A concomitant Cox-Maze procedure resulted in superior freedom from AF rates at every time point (both with and without antiarrhythmic drugs), ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security